Masimo (NASDAQ:MASI) Issues FY 2025 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.620-5.790 for the period, compared to the consensus earnings per share estimate of 5.320. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Masimo Stock Up 2.8%

MASI stock traded up $4.05 during trading on Tuesday, reaching $149.01. 1,439,249 shares of the company traded hands, compared to its average volume of 639,869. Masimo has a 12 month low of $133.70 and a 12 month high of $194.88. The business has a 50 day simple moving average of $144.80 and a 200 day simple moving average of $154.07. The company has a market capitalization of $8.09 billion, a price-to-earnings ratio of -17.49 and a beta of 1.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. The company had revenue of $617.00 million for the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%. On average, equities research analysts anticipate that Masimo will post 4.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MASI has been the subject of several recent research reports. Piper Sandler lifted their price target on Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating and issued a $198.00 price target on shares of Masimo in a research note on Thursday, September 11th. Zacks Research lowered Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Finally, Wall Street Zen raised Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $194.60.

Insider Transactions at Masimo

In related news, Director William R. Jellison purchased 3,000 shares of the company’s stock in a transaction on Monday, August 11th. The stock was bought at an average price of $145.98 per share, with a total value of $437,940.00. Following the completion of the transaction, the director owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. This represents a 167.60% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Masimo

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new stake in Masimo during the second quarter valued at approximately $86,000. Dynamic Technology Lab Private Ltd bought a new position in Masimo during the 1st quarter valued at $220,000. Tower Research Capital LLC TRC boosted its stake in Masimo by 12.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,516 shares of the medical equipment provider’s stock valued at $255,000 after purchasing an additional 166 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in Masimo during the 2nd quarter valued at $356,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Masimo by 1,267.1% during the 1st quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock valued at $367,000 after acquiring an additional 2,040 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.